GlassScriptPhysician profile
Wilfredo A Torres
NPI 1235453846
$3,065.47
in general payments reported to CMS, 2019-2025
28 companies · $579 in 2025
The $579 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $158 · 2021: $294 · 2022: $746 · 2023: $349 · 2024: $372 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,299.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $382.03 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Myovant Sciences INC. | $376.27 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $352.41 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Intuitive Surgical, INC. | $352.00 | 2019-2023 | Da Vinci Surgical System |
| Lilly USA, LLC | $265.16 | 2025 | Zepbound |
| Astellas Pharma US INC | $253.35 | 2023-2025 | Veozah |
| Therapeuticsmd, INC. | $143.43 | 2019-2022 | |
| Pfizer INC. | $129.49 | 2019-2023 | |
| Daiichi Sankyo INC. | $106.37 | 2022-2024 | Injectafer |
| Sumitomo Pharma America, INC. | $100.17 | 2024-2025 | Myfembree |
| Hologic Sales and Service, LLC | $76.75 | 2019-2025 | Aptima |
| Glaxosmithkline, LLC. | $59.41 | 2020-2023 | Bexsero, Shingrix, Pediarix |
| Allergan, INC. | $50.43 | 2019-2020 | |
| Baxter Healthcare | $46.80 | 2025 | Perclot |
| Amgen INC. | $45.46 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $36.39 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $35.36 | 2019-2023 | |
| Sage Therapeutics, LLC | $32.99 | 2024 | |
| Amarin Pharma, INC. | $30.83 | 2021 | |
| Organon LLC | $30.04 | 2024 | |
| Mayne Pharma Commercial LLC | $28.47 | 2025 | |
| Aspira Women'S Health INC | $24.67 | 2024 | Ova1 |
| Dilon Technologies, INC. | $24.03 | 2023 | Hemoblast Bellows |
| Amag Pharmaceuticals, INC. | $22.68 | 2019 | |
| Ironshore Pharmaceuticals INC. | $22.53 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.41 | 2020 | |
| Seqirus USA INC | $12.51 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilfredo Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.